Adults with type 2 diabetes and elevated cardiovascular risk who had their systolic blood pressure driven below 120 mm Hg experienced roughly one-fifth fewer major cardiac events than those managed to the conventional target below 140 mm Hg, according to the BPROAD trial, a large randomized study published in the New England Journal of Medicine. The result directly challenges findings from the earlier ACCORD BP trial, which tested the same blood pressure targets in diabetic patients but found no significant reduction in its primary composite outcome. With guideline committees in the United States and Europe weighing updates to blood pressure recommendations for people with diabetes, the new data injects fresh urgency into a clinical debate that has stalled for more than a decade.
Why the 120 mm Hg target matters for diabetic patients right now
For years, doctors treating patients with type 2 diabetes have faced a frustrating gap in the evidence. The ACCORD BP trial, published in the New England Journal of Medicine, compared an intensive systolic blood pressure target below 120 mm Hg against a standard target below 140 mm Hg in people with type 2 diabetes. That trial found no significant reduction in its primary composite outcome of major cardiovascular events, though it did show a reduction in stroke alongside more treatment-related adverse events in the intensive-control group. The mixed results left clinicians and guideline writers without a clear mandate to push blood pressure lower in this population.
BPROAD set out to resolve that uncertainty. Registered under the identifier NCT03808311, the trial was designed with a prespecified primary composite outcome of nonfatal stroke, nonfatal myocardial infarction, treated or hospitalized heart failure, and cardiovascular death. The study enrolled a substantially larger cohort than ACCORD BP and drew participants with higher baseline cardiovascular risk, factors that gave it greater statistical power to detect a meaningful difference between the two blood pressure targets.
The published BPROAD results report that intensive control to below 120 mm Hg reduced the risk of the composite cardiovascular endpoint by about 20% relative to the conventional target, with consistent trends across most prespecified subgroups. That effect size, while modest in absolute terms, is clinically important when multiplied across the large number of adults with diabetes and hypertension worldwide. It also aligns directionally with broader observational data linking lower systolic pressure to fewer heart attacks and strokes in high-risk populations.
The hypothesis embedded in the headline, that pushing systolic blood pressure below 120 mm Hg can cut heart attacks and strokes by about a fifth, rests on BPROAD’s event-rate data. A related question is whether the method of achieving that lower number matters. Patients in the intensive arm typically required higher-dose combination drug regimens rather than lifestyle changes alone. Whether those pharmacological strategies drive the benefit independently of how far blood pressure falls remains an open line of inquiry that the trial’s published data do not fully separate.
How BPROAD produced different answers than ACCORD BP
The contrast between BPROAD and ACCORD BP is not simply a matter of one trial succeeding where the other failed. Design differences explain much of the divergence. BPROAD’s peer-reviewed design paper, available in trial methodology reports, outlined broader eligibility criteria that captured patients at higher baseline cardiovascular risk than those in ACCORD BP. A larger sample size and longer follow-up period gave the trial more statistical room to detect event reductions that ACCORD BP may have been underpowered to find.
An accompanying editorial in the New England Journal of Medicine placed BPROAD in the context of both ACCORD BP and the SPRINT trial, which demonstrated clear cardiovascular benefits of intensive blood pressure lowering in non-diabetic adults. The editorial examined why results differed across these studies and discussed the generalizability of BPROAD’s findings, including the clinical tradeoffs involved in pushing blood pressure targets lower. ACCORD BP’s finding of more adverse events with intensive control had been a persistent concern, and the editorial weighed whether BPROAD’s design and population addressed those safety signals adequately.
Several features stand out. First, BPROAD appears to have enrolled patients with more established cardiovascular disease or multiple high-risk features, increasing the baseline event rate and therefore the potential absolute benefit of more aggressive blood pressure control. Second, background care has evolved in the years since ACCORD BP, with contemporary use of statins, antiplatelet therapy, and modern glucose-lowering drugs likely higher in BPROAD. These co-interventions may have altered both the risk profile and the tolerance of intensive blood pressure lowering, though the available summaries do not fully disentangle their contributions.
The BPROAD trial’s primary composite outcome was prespecified and documented in the trial registry before results were unblinded. That procedural detail matters because it guards against the possibility that researchers selected their outcome measure after seeing the data, a practice known as outcome switching that can inflate the apparent strength of findings. The registry entry and the design paper both confirm the composite endpoint was locked in from the start, lending credibility to the reported relative risk reduction.
Gaps in the BPROAD data that clinicians still need filled
Despite the strength of the headline finding, several pieces of the puzzle are missing from publicly accessible summaries. Full numeric event rates, hazard ratios, and confidence intervals from the BPROAD trial have not been broadly disseminated outside the paywalled article and its supplementary tables. Without those granular numbers, independent researchers cannot fully assess the magnitude and precision of the benefit or compare it head-to-head with ACCORD BP’s results on a statistical basis, including formal tests for heterogeneity between trials.
Detailed adverse-event data present another gap. ACCORD BP reported more treatment-related side effects, including serious hypotension, syncope, and electrolyte abnormalities, in the intensive-control group. Whether BPROAD observed a similar pattern, and at what frequency, is not yet clear from the editorial summary or abstract alone. For clinicians weighing whether to adopt a lower target for their diabetic patients, the balance between cardiovascular benefit and drug-related harm is the central practical question. Even a 20% relative reduction in major events could be offset in some patients if the price is frequent symptomatic hypotension, falls, or kidney injury.
Subgroup analyses by age, kidney function, or concurrent use of newer diabetes drugs such as SGLT2 inhibitors and GLP-1 receptor agonists have not been fully released from the trial database. Those breakdowns matter because they can reveal whether the benefit of intensive control is uniform or concentrated in particular populations, such as younger patients with preserved renal function or those already receiving cardio-protective glucose-lowering agents. Without that level of detail, clinicians must apply the overall trial result cautiously, tailoring decisions to individual risk profiles rather than assuming a one-size-fits-all effect.
Another unanswered issue is durability. BPROAD’s follow-up period, while longer than ACCORD BP’s, still represents a finite snapshot in the life course of a chronic disease. It remains uncertain whether the observed reduction in cardiovascular events will translate into sustained mortality benefits over a decade or more, or whether any early advantage might narrow as competing risks emerge. Long-term observational extensions of the trial cohort, if conducted, will be important to clarify whether “legacy effects” of intensive blood pressure lowering exist in this high-risk diabetic population.
What the new evidence means for practice and guidelines
For now, BPROAD offers the most compelling randomized evidence to date that targeting a systolic blood pressure below 120 mm Hg can reduce major cardiovascular events in adults with type 2 diabetes and high baseline risk. In combination with SPRINT’s findings in non-diabetic patients, the trial strengthens the argument that intensive blood pressure control should at least be considered for many people with diabetes, particularly those with prior cardiovascular events or multiple risk factors.
Yet the data gaps and safety uncertainties argue against a blanket mandate. A pragmatic approach is likely to emerge: discuss intensive targets with appropriate patients, emphasize home monitoring and careful titration of medications, and prioritize those at the highest absolute risk who stand to gain the most. As full BPROAD data become more widely available and guideline committees complete their reviews, recommendations may shift toward more aggressive blood pressure goals in diabetes, but with explicit caveats around individualized care and close follow-up.
In the meantime, BPROAD has already changed the conversation. Where ACCORD BP once cast doubt on the value of pushing systolic pressure below 120 mm Hg in diabetes, the new evidence suggests that, for many high-risk patients, lower really may be better-provided clinicians have the tools, time, and data to manage the risks that come with aiming for that ambitious target.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
